Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

ClinicalTrials.gov ID: NCT01939223

Public ClinicalTrials.gov record NCT01939223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy.

Study identification

NCT ID
NCT01939223
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bayer
Industry
Enrollment
25 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2, 2013 (Actual)
Primary completion
Aug 29, 2016 (Actual)
Completion
Aug 29, 2016 (Actual)
Last update posted
Oct 20, 2017

2013 – 2016

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Not listed Laguna Hills California 92653 —
Not listed Los Angeles California 90033 —
Not listed Los Angeles California 90089 —
Not listed Los Angeles California 90095 —
Not listed New Haven Connecticut 06520-8064 —
Not listed New Orleans Louisiana 70121 —
Not listed Baltimore Maryland 21201-1595 —
Not listed Detroit Michigan 48202 —
Not listed Rochester Minnesota 55905 —
Not listed Omaha Nebraska 68106 —
Not listed New Brunswick New Jersey 08903-2681 —
Not listed Buffalo New York 14263-0001 —
Not listed New York New York 10021 —
Not listed Syracuse New York 13210 —
Duke University Medical Center Durham North Carolina 27710 —
Not listed Philadelphia Pennsylvania 19104 —
Not listed Chattanooga Tennessee 37421 —
Not listed Germantown Tennessee 38138 —
Not listed Dallas Texas 75390 —
Not listed Richmond Virginia 23298-0037 —
Not listed Kirkland Washington 98034 —
Not listed Seattle Washington 98101 —
Not listed Seattle Washington 98109 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01939223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2017 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01939223 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →